厉有名附属第一医院 | 医学院临床医学内科学(消化系病)个人简介:厉有名内科学教授、主任医师、博士生导师，现任浙江大学医学院附属第一医院消化内科主任、学科带头人 浙江省医学会内科学分会主任委员、浙江省医师协会内科医师分会会长 中华医师协会消化医师分会常委和消化内镜医师分会常委、第13届中华医学会内科学分会主任委员。先后承担“十二五”国家支撑计划1项，国家自然科学基金重点项目1项，参与国家863重大项目2项获国家专利4项发表研究论文150余篇，研究成果先后获得国家教育部科技进步奖一等奖1项浙江省科技进步奖一等奖1项、二等奖5项，多次获得浙江省医药卫生科技创新奖一等奖。研究与成果:1 课题项目名称项目来源项目编号起止时间经费总额本人排名/总人数国人脂肪性肝病早期诊断和筛查技术研究国家科技支撑计划2012BA106B042012.1-2015.12297万元1/14脂代谢紊乱疾病发生发展进程中的标志性代谢产物研究国家973计划子课题2012CB5249052012.1-2016.12200万元1/16解偶联蛋白家族在非酒精性脂肪性肝病慢性化过程中的作用及其机制研究国家自然科学基金重点项目812300122013.1-2017.12270万元1/62 专利厉有名.乙醇代谢相关酶基因多态性检测芯片及其制备方法和用途.发明专利.2006:1/2厉有名.瘦素和瘦素受体基因多态性检测芯片及其制备方法和用途.发明专利.2008:1/1厉有名.PPAR-α和PPAR-γ基因多态性检测芯片的制备方法和用途.发明专利.2008:1/2厉有名.一种特异抑制p21基因表达的siRNA及其应用.发明专利.2016:4/43出版书籍书名著作类型出版年月出版社名称所有作者姓名本人字数/总字数（万字）普通内科学高级教程国家级2017-1-1中华医学电子音像出版社主编 刘又宁副主编 厉有名20/40万字副主编胃肠病学国家级2015-10人民卫生出版社1万字编委中华医学百科全书-临床医学消化病学国家级2015中国协和医科大学出版社2万字编委发表论文:近4年部分论文列表1）Li M Xu C Shi J Ding J Wan X Chen D Gao J Li C Zhang J Lin Y Tu Z Kong X Li Y Yu C. Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway. Gut. 2017. doi: 10.1136/gutjnl-2017-313778. (IF:16.658)2）Wan X#Xu C#Lin YLu C Li D Sang J He HLiu XLi Y Yu C.Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism. J Hepatol201664(4):925-32.(IF 12.486)3)Xu C Wan XXu LWeng H Yan M Miao M SunY Xu GDooley S Li Y Yu C.Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: one stone hits two birds. J Hepatol. 201562(6):1412-9. (IF 12.486)4） Zhu JZ Wang YM Zhou QY Zhu KF Yu CH Li YM.Systematic review with meta-analysis: alcohol consumption and the risk of colorectal adenoma.Aliment Pharmacol Ther. 2014 Aug;40(4):325-37. (IF=5.487)5）Shen Z Munker SZhou B Li LYu C Li Y. The accuracies of diagnosing pancrease Divisum by Magnetic Resonance Cholangiopancreatography and Endoscopic Ultrasound: A Systematic review and meta-analysis. Sci Rep. 2016.13;6:35389. (IF 4.259)6) Xu C Chen Y Xu L Miao M Li YYu C. Serum complement C3 levels are associated with nonalcoholic fatty liver disease indepantently of metabolic syndrome features in a Chinese population. Sci Rep. 2016.6:23279. (IF 4.259)7) Wang JXu C Xun YLuZShi JYu C，Li Y.ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese population. Sci Rep. 2015.16;5:16494. (IF 4.259)8) Wang J Zhu W Huang S Xu L Miao M Wu C Yu C Li Y Xu C. Serum apoB levels independently predict the development of non-alcoholic fatty liver disease: A 7-year prospective study. Liver Int. 2017; 37(8):1202-1208. (IF:4.116)9）Li L Li G Yu C Shen Z Xu C Feng Z Zhang X Li Y. A role of microRNA-370 in hepatic ischaemia-reperfusion injury by targeting transforming growth factor-β receptor II. Liver Int. 2015 Apr;35(4):1124-32. (IF: 4.85)10）Dai YN Zhu JZ Fang ZY Zhao DJ Wan XY Zhu HT Yu CH Li YM. A case-control study: Association between serum neuregulin 4 level and non-alcoholic fatty liver disease. Metabolism. 2015 Dec;64(12):1667-73. (IF: 3.894)11）Zhu JZ Zhu HT Dai YN Li CX Fang ZY Zhao DJ Wan XY Wang YM Wang F Yu CH Li YM. Serum periostin is a potential biomarker for non-alcoholic fatty liver disease: a case-control study. Endocrine. 2016 Jan;51(1):91-100. (IF: 3.878) 12）Shen Z Munker S Luo F Ma H Yu C Li Y. Effect of Non-Alcoholic Fatty Liver Disease on Estimated Glomerular Filtration Rate Could Be Dependent on Age. PLoS One. 2015 Jun 18;10(6):e0130614. (IF: 3.234)13）Zhu JZ Yan TL Yu CH Wan XY Wang YM Li YM.Is national socioeconomic status related to prevalence of irritable bowel syndrome?J Gastroenterol Hepatol. 2014 Aug;29(8):1595-602. (IF=3.627)14）Shen Z Munker S Wang C Xu L Ye H Chen H Xu G Zhang H Chen L Yu C Li Y.Association between alcohol intake overweight and serum lipid levels and the risk analysis associated with the development of dyslipidemia.J Clin Lipidol. 2014 May-Jun;8(3):273-8. (IF=3.587)15）Wang JW Wan XY Zhu HT Lu C Yu WL Yu CH Shen Z Li YM. Lipotoxic effect of p21 on free fatty acid-induced steatosis in L02 cells.PLoS One. 2014 Apr 30;9(4):e96124. (IF= 3.534)16）Chen Y Yu C Li Y.Physical activity and risks of esophageal and gastric cancers: a meta-analysis.PLoS One. 2014 Feb 6;9(2):e88082. (IF= 3.534)17）Shen C Wu X Xu C Yu C Chen P Li Y.Association of cholecystectomy with metabolic syndrome in a Chinese population.PLoS One. 2014 Feb 5;9(2):e88189. (IF= 3.534)18）Yang L Chen Y Zhang B Chen C Yue M Du J Yu C Li Y.Increased diagnostic yield of capsule endoscopy in patients with chronic abdominal pain.PLoS One. 2014 Jan 31;9(1):e87396. (IF= 3.534)19）Li L Ke Y Yu C Li G Yang N Zhang J Li Y. Antibiotic resistance of Helicobacter pylori in Chinese children: A multicenter retrospective study over 7 years. Helicobacter. 2017; 22(3):e12373. (IF: 3.429)20) Chen Y Huang H Xu C Yu C Li Y. Long Non-Coding RNA Profiling in a Non-Alcoholic Fatty Liver Disease Rodent Model: New Insight into Pathogenesis. Int J Mol Sci. 2017; 18(1). pii: E21. (IF: 3.226)21）Zhu J Wan X Wang Y Zhu K Li C Yu C Li Y. Serum fetuin B level increased in subjects of nonalcoholic fatty liver disease: a case-control study. Endocrine. 2016 Sep 14. (IF: 3.279)22）Zhu JZ Zhu HT Dai YN Li CX Fang ZY Zhao DJ Wan XY Wang YM Wang F Yu CH Li YM. Serum periostin is a potential biomarker for non-alcoholic fatty liver disease: a case-control study. Endocrine. 2016 Jan;51(1):91-100. (IF: 3.279)23） Zhu J Wan X Wang Y Zhu K Li C Yu C Li Y. Serum fetuin B level increased in subjects of nonalcoholic fatty liver disease: a case-control study. Endocrine. 2017; 56(1): 208-211. (IF: 3.131)